A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly
A phase 2/3 trial of Selinexor, Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by Karyopharm Therapeutics Inc, active and no longer recruiting.
Overview
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma is a phase 2/3 interventional study registered as NCT04442022 by Karyopharm Therapeutics Inc, with 501 participants planned, started 2020-09-03 and due to reach its primary completion in 2026-12. Interventions recorded: Selinexor (combination therapy), Selinexor (combination therapy), Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy). Conditions listed: Relapsed/Refractory Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSelinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Shares Karyopharm Therapeutics, Selinexor, Diffuse large B-cell lymphoma.
- TrialA Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac
Shares Karyopharm Therapeutics, Selinexor, Dexamethasone.
- TrialXPORT-EC-042 / ENGOT-EN20 / GOG-3083
Shares Karyopharm Therapeutics, Selinexor.
- TrialSelinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Karyopharm Therapeutics, Selinexor, Dexamethasone.
- TrialStudy of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Shares Karyopharm Therapeutics, Selinexor.
- TrialStudy of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Shares Rituximab, Gemcitabine, Diffuse large B-cell lymphoma.
- TrialPembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Shares Dexamethasone, Gemcitabine, Cisplatin.
- CompanyAntengene
Shares Selinexor, Diffuse large B-cell lymphoma.